News related to Sustiva (Efavirenz) and/or conditions it is approved for
Better Outcomes In HIV-Infected Adults Treated Initially With Efavirenz-Based Therapies
Source: Compliance News From Medical News Today [2008.10.15]
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted.
New HIV Infections Could End In United States In 30 Years
Source: HIV / AIDS News From Medical News Today [2008.11.20]
When the CDC announced this summer that new HIV infections in the U.S. have been 40 percent higher annually than previously had been estimated, a key part of the equation was left out of the story: No vaccine or cure is in sight and, yet, new HIV infections are down from 130,000 annually from the peak of the epidemic with HIV prevention efforts having played a critical role in this reduction.
STEP Study Shows HIV Vaccine From Merck Does Not Protect Against HIV Infection
Source: Immune System / Vaccines News From Medical News Today [2008.11.17]
The failure of the latest HIV vaccine from Merck is analysed in two Articles and a Comment published early Online and in an upcoming edition of The Lancet. The vaccine failed to give any protection from HIV infection, and the usefulness of non-human models for HIV vaccine development have been called into question.
Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]
Title: Herpes Suppression May Not Prevent HIV Infection
Category: Health News
Created: 6/20/2008 2:00:00 AM
Last Editorial Review: 6/20/2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir Vs. Lopinavir/ritonavir As Part Of HIV Combination Therapy In Treatment-Experienced Adults
Source: Conferences News From Medical News Today [2008.11.19]
Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naive, treatment-experienced HIV-1 infected adults. A 96-week resistance analysis from the study, known as TITAN, was presented in an oral presentation at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, UK on November 13, 2008.
Domestic Strategy For Combating HIV/AIDS In U.S. Should Mirror PEPFAR, Opinion Piece Says
Source: HIV / AIDS News From Medical News Today [2008.11.18]
President Bush's "efforts to reduce HIV infection and mortality rates through the
Case Of Patient "Cured" Of HIV Baffles Doctors
Source: Blood / Hematology News From Medical News Today [2008.11.14]
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia.
HIV Replication Inhibited By Herpes Drug, But With A Price
Source: MRSA / Drug Resistance News From Medical News Today [2008.11.07]
The anti-herpes drug acyclovir can also directly slow down HIV infection by targeting the reverse transcriptase (RT) enzyme, researchers report in this week's JBC. This beneficial effect does pose a risk though, as HIV-infected cells treated with acyclovir promote the emergence of multi-drug resistant HIV variants. HIV and herpes (HSV) are two of the most common sexually transmitted diseases worldwide, and individuals frequently become co-infected with both.
|
